Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models

Overview

Journal Front Vet Sci

Specialty Veterinary Medicine

Date 2022 Apr 11

PMID 35400105

Authors

Longfei Zhang

Hongbing Xie

Yongqiang Wang

Hongjuan Wang

Jianhe Hu

Gaiping Zhang

Affiliations

Soon will be listed here.

Abstract

Pharmacokinetic/pharmacodynamic (PK/PD) integration models are used to investigate the antimicrobial activity characteristics of drugs targeting pathogenic bacteria through comprehensive analysis of the interactions between PK and PD parameters. PK/PD models have been widely applied in the development of new drugs, optimization of the dosage regimen, and prevention and treatment of drug-resistant bacteria. In PK/PD analysis, minimal inhibitory concentration (MIC) is the most commonly applied PD parameter. However, accurately determining MIC is challenging and this can influence the therapeutic effect. Therefore, it is necessary to optimize PD indices to generate more rational results. Researchers have attempted to optimize PD parameters using mutant prevention concentration (MPC)-based PK/PD models, multiple PD parameter-based PK/PD models, kill rate-based PK/PD models, and others. In this review, we discuss progress on PD parameters for PK/PD models to provide a valuable reference for drug development, determining the dosage regimen, and preventing drug-resistant mutations.

Citing Articles

Adaptation of an one-compartment pharmacodynamic chemostat for testing efficacy of ceftazidime against outside a BSL3 facility.

Zamri H, Mohd Ali M, Shaari A, Mohd Mazalan N, Ahmad N, Nor Amdan N MethodsX. 2025; 14:103167.

PMID: 39897649 PMC: 11782592. DOI: 10.1016/j.mex.2025.103167.

PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance.

Onita T, Ishihara N, Yano T Antibiotics (Basel). 2025; 14(1).

PMID: 39858377 PMC: 11759776. DOI: 10.3390/antibiotics14010092.

Dynamic PK/PD Infection Models for the Development and Optimisation of Antimicrobial Regimens: A Narrative Review.

Wale Y, Roberts J, Sime F Antibiotics (Basel). 2025; 13(12.

PMID: 39766591 PMC: 11672834. DOI: 10.3390/antibiotics13121201.

Evaluation of different PK/PD ratios of three enrofloxacin preparations on the clinical response of pneumonic calves.

Gutierrez L, Mejia-Arthur I, Posadas-Manzano E, Rodriguez-Becerril N, Lopez-Ordaz R, Sumano H J Vet Sci. 2025; 26(1):e7.

PMID: 39749382 PMC: 11799083. DOI: 10.4142/jvs.24161.

Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model.

Huang Z, Li W, Zhang R, Li Y, Li X, Bian X Front Microbiol. 2025; 15:1516979.

PMID: 39741587 PMC: 11685127. DOI: 10.3389/fmicb.2024.1516979.

References

Blondeau J, Fitch S . Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis. PLoS One. 2019; 14(1):e0210154. PMC: 6328246. DOI: 10.1371/journal.pone.0210154. View

Yang F, Chen P, Wang H, Xing X, Wang S, Ishaq H . Comparative Minimal Inhibitory and Mutant Prevention Concentration of Eight Antimicrobial Agents Against . Microb Drug Resist. 2021; 28(2):229-235. DOI: 10.1089/mdr.2021.0228. View

Zeng D, Sun M, Lin Z, Li M, Gehring R, Zeng Z . Pharmacokinetics and Pharmacodynamics of Tildipirosin Against in a Murine Lung Infection Model. Front Microbiol. 2018; 9:1038. PMC: 5968193. DOI: 10.3389/fmicb.2018.01038. View

Cui J, Liu Y, Wang R, Tong W, Drlica K, Zhao X . The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis. 2006; 194(11):1601-8. DOI: 10.1086/508752. View

Lees P, Giraudel J, Landoni M, Toutain P . PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther. 2004; 27(6):491-502. DOI: 10.1111/j.1365-2885.2004.00618.x. View

Sumi C, Heffernan A, Lipman J, Roberts J, Sime F . What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clin Pharmacokinet. 2019; 58(11):1407-1443. DOI: 10.1007/s40262-019-00791-z. View

Tangden T, Ramos Martin V, Felton T, Nielsen E, Marchand S, Bruggemann R . The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017; 43(7):1021-1032. DOI: 10.1007/s00134-017-4780-6. View

Sy S, Zhuang L, Xia H, Beaudoin M, Schuck V, Nichols W . A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa. J Antimicrob Chemother. 2018; 73(5):1295-1304. DOI: 10.1093/jac/dkx537. View

Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F, Gustafsson T . Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against in a Dynamic Hollow Fiber Infection Model. Front Pharmacol. 2021; 12:682135. PMC: 8175963. DOI: 10.3389/fphar.2021.682135. View

10.

Cao C, Qu Y, Sun M, Qiu Z, Huang X, Huai B . In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves. Front Microbiol. 2015; 6:759. PMC: 4513234. DOI: 10.3389/fmicb.2015.00759. View

11.

Mouton J, Vinks A . Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet. 2005; 44(2):201-10. DOI: 10.2165/00003088-200544020-00005. View

12.

Lei Z, Liu Q, Xiong J, Yang B, Yang S, Zhu Q . Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against in Pigs. Front Pharmacol. 2017; 8:542. PMC: 5566571. DOI: 10.3389/fphar.2017.00542. View

13.

Yao Q, Gao L, Xu T, Chen Y, Yang X, Han M . Amoxicillin Administration Regimen and Resistance Mechanisms of Established in Tissue Cage Infection Model. Front Microbiol. 2019; 10:1638. PMC: 6662548. DOI: 10.3389/fmicb.2019.01638. View

14.

Kitamura Y, Yoshida K, Kusama M, Sugiyama Y . A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics. Drug Metab Pharmacokinet. 2014; 29(6):455-62. DOI: 10.2133/dmpk.DMPK-14-RG-013. View

15.

Onufrak N, Forrest A, Gonzalez D . Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther. 2016; 38(9):1930-47. PMC: 5039113. DOI: 10.1016/j.clinthera.2016.06.015. View

16.

Nolting A, Dalla Costa T, Rand K, Derendorf H . Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res. 1996; 13(1):91-6. DOI: 10.1023/a:1016085402278. View

17.

Drlica K, Zhao X . Mutant selection window hypothesis updated. Clin Infect Dis. 2007; 44(5):681-8. DOI: 10.1086/511642. View

18.

Dorey L, Pelligand L, Cheng Z, Lees P . Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. J Vet Pharmacol Ther. 2017; 40(5):505-516. PMC: 5600110. DOI: 10.1111/jvp.12385. View

19.

Zhang N, Gu X, Ye X, Wu X, Zhang B, Zhang L . The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum. Front Microbiol. 2016; 7:653. PMC: 4854994. DOI: 10.3389/fmicb.2016.00653. View

20.

Mueller M, de la Pena A, Derendorf H . Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother. 2004; 48(2):369-77. PMC: 321563. DOI: 10.1128/AAC.48.2.369-377.2004. View